IL177588A0 - Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants - Google Patents
Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulantsInfo
- Publication number
- IL177588A0 IL177588A0 IL177588A IL17758806A IL177588A0 IL 177588 A0 IL177588 A0 IL 177588A0 IL 177588 A IL177588 A IL 177588A IL 17758806 A IL17758806 A IL 17758806A IL 177588 A0 IL177588 A0 IL 177588A0
- Authority
- IL
- Israel
- Prior art keywords
- aerosolized
- anticoagulants
- pulmonary tissue
- fibrin clots
- preventing fibrin
- Prior art date
Links
- 239000003146 anticoagulant agent Substances 0.000 title abstract 2
- 229940127219 anticoagulant drug Drugs 0.000 title abstract 2
- 102000009123 Fibrin Human genes 0.000 title 1
- 108010073385 Fibrin Proteins 0.000 title 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title 1
- 229950003499 fibrin Drugs 0.000 title 1
- 210000004879 pulmonary tissue Anatomy 0.000 title 1
- 108090000935 Antithrombin III Proteins 0.000 abstract 2
- 102100022977 Antithrombin-III Human genes 0.000 abstract 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 208000004852 Lung Injury Diseases 0.000 abstract 1
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 abstract 1
- 102100021463 Seipin Human genes 0.000 abstract 1
- 101710127791 Seipin Proteins 0.000 abstract 1
- 229940122055 Serine protease inhibitor Drugs 0.000 abstract 1
- 101710102218 Serine protease inhibitor Proteins 0.000 abstract 1
- 206010069363 Traumatic lung injury Diseases 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 230000002429 anti-coagulating effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 229960005348 antithrombin iii Drugs 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 231100000515 lung injury Toxicity 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 239000003001 serine protease inhibitor Substances 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54623604P | 2004-02-20 | 2004-02-20 | |
| US11/057,522 US20050192226A1 (en) | 2004-02-20 | 2005-02-14 | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
| PCT/US2005/004604 WO2005081816A2 (en) | 2004-02-20 | 2005-02-15 | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL177588A0 true IL177588A0 (en) | 2008-03-20 |
Family
ID=34889863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL177588A IL177588A0 (en) | 2004-02-20 | 2006-08-20 | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20050192226A1 (https=) |
| EP (2) | EP1725244B1 (https=) |
| JP (2) | JP2007533657A (https=) |
| KR (3) | KR20060130661A (https=) |
| AT (1) | ATE493135T1 (https=) |
| AU (1) | AU2005216044B2 (https=) |
| CA (1) | CA2557411A1 (https=) |
| DE (1) | DE602005025610D1 (https=) |
| IL (1) | IL177588A0 (https=) |
| WO (1) | WO2005081816A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2480790A1 (en) * | 2002-04-01 | 2003-10-16 | Kazunori Murakami | Use of antithrombin iii in treating acute lung injury |
| US20050169908A1 (en) * | 2004-01-23 | 2005-08-04 | Kazunori Murakami | Use of aerosolized antithrombin to treat acute lung injury |
| US20050192226A1 (en) * | 2004-02-20 | 2005-09-01 | Perenlei Enkhbaatar | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
| US20050245444A1 (en) * | 2004-04-30 | 2005-11-03 | Yann Echelard | Method of using recombinant human antithrombin for neurocognitive disorders |
| US20060121004A1 (en) * | 2004-12-07 | 2006-06-08 | Yann Echelard | Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin |
| ES2811526T3 (es) | 2010-12-30 | 2021-03-12 | Lab Francais Du Fractionnement | Glicoles como agentes de inactivación de patógenos |
| WO2014089327A1 (en) * | 2012-12-05 | 2014-06-12 | National Jewish Health | Treatment for airway cast obstruction |
| EP3594230A1 (en) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
| US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| EP3016729B1 (fr) | 2013-07-05 | 2020-03-25 | Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme | Matrice de chromatographie d'affinité |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6127347A (en) * | 1994-01-12 | 2000-10-03 | Univ Michigan | Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes |
| US6355626B1 (en) * | 1994-05-13 | 2002-03-12 | The Trustees Of The University Of Pennsylvania | Antithrombin agents in treatment of asthma |
| US5843705A (en) * | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
| US7045585B2 (en) * | 1995-11-30 | 2006-05-16 | Hamilton Civic Hospital Research Development Inc. | Methods of coating a device using anti-thrombin heparin |
| US6063593A (en) * | 1996-11-12 | 2000-05-16 | University Of Southern California University Park Campus | TGFβ1 responsive bone marrow derived cells to express a recombinant protein |
| US6124257A (en) * | 1997-08-28 | 2000-09-26 | Lezdey; John | Method of treatment |
| AU2440802A (en) * | 2000-10-18 | 2002-04-29 | Massachusetts Inst Technology | Methods and products related to pulmonary delivery of polysaccharides |
| DE10132307A1 (de) | 2001-07-06 | 2003-01-30 | Aventis Behring Gmbh | Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS |
| CA2480790A1 (en) * | 2002-04-01 | 2003-10-16 | Kazunori Murakami | Use of antithrombin iii in treating acute lung injury |
| US20050169908A1 (en) * | 2004-01-23 | 2005-08-04 | Kazunori Murakami | Use of aerosolized antithrombin to treat acute lung injury |
| US20050192226A1 (en) * | 2004-02-20 | 2005-09-01 | Perenlei Enkhbaatar | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
-
2005
- 2005-02-14 US US11/057,522 patent/US20050192226A1/en not_active Abandoned
- 2005-02-15 WO PCT/US2005/004604 patent/WO2005081816A2/en not_active Ceased
- 2005-02-15 JP JP2006554156A patent/JP2007533657A/ja active Pending
- 2005-02-15 KR KR1020067019275A patent/KR20060130661A/ko not_active Ceased
- 2005-02-15 EP EP05713495A patent/EP1725244B1/en not_active Expired - Lifetime
- 2005-02-15 CA CA002557411A patent/CA2557411A1/en not_active Abandoned
- 2005-02-15 EP EP10177819A patent/EP2322189A3/en not_active Withdrawn
- 2005-02-15 DE DE602005025610T patent/DE602005025610D1/de not_active Expired - Lifetime
- 2005-02-15 AU AU2005216044A patent/AU2005216044B2/en not_active Ceased
- 2005-02-15 AT AT05713495T patent/ATE493135T1/de not_active IP Right Cessation
- 2005-02-15 KR KR1020097027466A patent/KR20100017971A/ko not_active Abandoned
- 2005-02-15 KR KR1020117015353A patent/KR20110084555A/ko not_active Ceased
-
2006
- 2006-08-20 IL IL177588A patent/IL177588A0/en unknown
-
2010
- 2010-09-10 US US12/879,235 patent/US20110070167A1/en not_active Abandoned
-
2011
- 2011-05-16 JP JP2011109632A patent/JP2011162555A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005081816A3 (en) | 2007-02-01 |
| EP1725244A4 (en) | 2009-08-12 |
| KR20060130661A (ko) | 2006-12-19 |
| EP1725244B1 (en) | 2010-12-29 |
| DE602005025610D1 (de) | 2011-02-10 |
| WO2005081816A2 (en) | 2005-09-09 |
| US20110070167A1 (en) | 2011-03-24 |
| US20050192226A1 (en) | 2005-09-01 |
| JP2007533657A (ja) | 2007-11-22 |
| ATE493135T1 (de) | 2011-01-15 |
| EP2322189A2 (en) | 2011-05-18 |
| KR20100017971A (ko) | 2010-02-16 |
| KR20110084555A (ko) | 2011-07-25 |
| AU2005216044A1 (en) | 2005-09-09 |
| JP2011162555A (ja) | 2011-08-25 |
| AU2005216044B2 (en) | 2011-07-14 |
| CA2557411A1 (en) | 2005-09-09 |
| EP1725244A2 (en) | 2006-11-29 |
| EP2322189A3 (en) | 2011-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL177588A0 (en) | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants | |
| WO2001093846A3 (en) | Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans | |
| AR039515A1 (es) | Proteinas de fusion de trombomodulina dirigidas al factor tisular como anticoagulantes | |
| WO2007119104A3 (en) | Secretion clearing patient airway management system | |
| NO20076206L (no) | Kombinasjon av PDE4 inhibitor romflumilast og et tetrahydrobioterin-derivativ | |
| HRP20080439T3 (hr) | Nova kombinacija antikolinergika i beta mimetika za liječenje respiratornih bolesti | |
| WO2007091266A3 (en) | Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases | |
| MXPA04000793A (es) | Novedoso metodo terapeutico. | |
| CY1117571T1 (el) | Συνδυασμος αντιχολινεργικων και ανταγωνιστων υποδοχεα λευκοτριενιου για την αγωγη αναπνευστικων νοσηματων | |
| WO2009042962A3 (en) | Antidotes for factor xa inhibitors and methods of using the same | |
| DE602006004009D1 (de) | 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen | |
| WO2005041864A3 (en) | Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method | |
| WO2008127654A3 (en) | Methods and compositions for intra-articular coagulation proteins | |
| WO2005072139A3 (en) | Use of aerosolized antithrombin to treat acute lung injury | |
| PL1799231T3 (pl) | Zastosowanie cyklodekstryny do leczenia i zapobiegania chorobom zapalnym oskrzeli | |
| WO2003084476A3 (en) | Treatment of lung disorder | |
| MXPA03011702A (es) | Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias. | |
| WO2006108039A3 (en) | Substituted azetidinones | |
| ATE451136T1 (de) | Thrombusabsaugkatheter | |
| NO20073909L (no) | Forstover-formulering | |
| WO2005113006A3 (en) | Use of dipyridamole for treatment of resistance to platelet inhibitors | |
| DK1511466T3 (da) | Anvendelse af glycosaminoglycaner, såsom for eksempel heparin, til behandling af respirationslidelser, såsom COPD | |
| WO2006026998A8 (en) | Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis | |
| WO2006083322A3 (en) | Methods for the treatment and prevention of infection using anti-selectin agents | |
| SE9303612D0 (sv) | New use |